Zamifenacin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526580

CAS#: 127308-82-1 (free)

Description: Zamifenacin, also known as UK-76654, is a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.


Chemical Structure

img
Zamifenacin
CAS# 127308-82-1 (free)

Theoretical Analysis

MedKoo Cat#: 526580
Name: Zamifenacin
CAS#: 127308-82-1 (free)
Chemical Formula: C27H29NO3
Exact Mass: 415.2147
Molecular Weight: 415.533
Elemental Analysis: C, 78.04; H, 7.03; N, 3.37; O, 11.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 127308-82-1 (free)   127308-98-9 (fumarate)  

Synonym: UK 76654; UK76654; UK-76654; Zamifenacin

IUPAC/Chemical Name: (R)-3-(benzhydryloxy)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)piperidine

InChi Key: BDNFQGRSKSQXRI-XMMPIXPASA-N

InChi Code: InChI=1S/C27H29NO3/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2/t24-/m1/s1

SMILES Code: N1(CCC2=CC(OCO3)=C3C=C2)C[C@H](OC(C4=CC=CC=C4)C5=CC=CC=C5)CCC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 415.533 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Houghton LA, Rogers J, Whorwell PJ, Campbell FC, Williams NS, Goka J. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1997 Jun;11(3):561-8. PubMed PMID: 9218083.

2: Amacher DE, Fasulo LM, Charuel C, Comby P, Beaumont K. In vitro toxicity of zamifenacin (UK-76,654) and metabolites in primary hepatocyte cultures. Xenobiotica. 1998 Sep;28(9):895-908. PubMed PMID: 9764931.

3: Watson N, Reddy H, Stefanich E, Eglen RM. Characterization of the interaction of zamifenacin at muscarinic receptors in vitro. Eur J Pharmacol. 1995 Oct 16;285(2):135-42. PubMed PMID: 8566131.

4: Beaumont KC, Causey AG, Coates PE, Smith DA. Pharmacokinetics and metabolism of zamifenacin in mouse, rat, dog and man. Xenobiotica. 1996 Apr;26(4):459-71. PubMed PMID: 9173686.

5: Hughes T, Wright AR, Owen JP, Keir MJ. Computerized planimetry in the objective assessment of the antispasmodic effect of Zamifenacin in double contrast barium enemas. Br J Radiol. 1996 Apr;69(820):301-5. PubMed PMID: 8665128.

6: Barlow RB, Bond SM, Branthwaite AG, Jackson O, McQueen DS, Smith KM, Smith PJ. Selective blockade of M2 and M3 muscarinic receptors by hexahydrobenzyl-fourdapine and a comparison with zamifenacin. Br J Pharmacol. 1995 Dec;116(7):2897-902. PubMed PMID: 8680722; PubMed Central PMCID: PMC1909210.

7: Golding JF, Stott JR. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br J Clin Pharmacol. 1997 Jun;43(6):633-7. PubMed PMID: 9205824; PubMed Central PMCID: PMC2042789.

8: Wallis RM. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists. Life Sci. 1995;56(11-12):861-8. PubMed PMID: 10188786.

9: Zholos AV, Bolton TB. Muscarinic receptor subtypes controlling the cationic current in guinea-pig ileal smooth muscle. Br J Pharmacol. 1997 Nov;122(5):885-93. PubMed PMID: 9384504; PubMed Central PMCID: PMC1564999.

10: Cossy J. Selective methodologies for the synthesis of biologically active piperidinic compounds. Chem Rec. 2005;5(2):70-80. Review. PubMed PMID: 15825169.

11: Boyd DF, Millar JA, Watkins CS, Mathie A. The role of Ca2+ stores in the muscarinic inhibition of the K+ current IK(SO) in neonatal rat cerebellar granule cells. J Physiol. 2000 Dec 1;529 Pt 2:321-31. PubMed PMID: 11101643; PubMed Central PMCID: PMC2270195.

12: Choppin A, Eglen RM, Hegde SS. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br J Pharmacol. 1998 Jul;124(5):883-8. PubMed PMID: 9692772; PubMed Central PMCID: PMC1565469.

13: Preiksaitis HG, Laurier LG. Pharmacological and molecular characterization of muscarinic receptors in cat esophageal smooth muscle. J Pharmacol Exp Ther. 1998 May;285(2):853-61. PubMed PMID: 9580636.

14: Watson N, Magnussen H, Rabe KF. Pharmacological characterization of the muscarinic receptor subtype mediating contraction of human peripheral airways. J Pharmacol Exp Ther. 1995 Sep;274(3):1293-7. PubMed PMID: 7562501.

15: Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. PubMed PMID: 10374898.

16: Lin S, Kajimura M, Takeuchi K, Kodaira M, Hanai H, Kaneko E. Expression of muscarinic receptor subtypes in rat gastric smooth muscle: effect of M3 selective antagonist on gastric motility and emptying. Dig Dis Sci. 1997 May;42(5):907-14. PubMed PMID: 9149041.

17: Ahfat NM, Buckton G, Burrows R, Ticehurst MD. An exploration of inter-relationships between contact angle, inverse phase gas chromatography and triboelectric charging data. Eur J Pharm Sci. 2000 Jan;9(3):271-6. PubMed PMID: 10594384.

18: Choppin A. Muscarinic receptors in isolated urinary bladder smooth muscle from different mouse strains. Br J Pharmacol. 2002 Oct;137(4):522-8. PubMed PMID: 12359634; PubMed Central PMCID: PMC1573519.

19: Choppin A, Eglen RM. Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. Br J Pharmacol. 2001 Aug;133(7):1035-40. PubMed PMID: 11487513; PubMed Central PMCID: PMC1572871.

20: Dunphy RC, Verne GN. Drug treatment options for irritable bowel syndrome: managing for success. Drugs Aging. 2001;18(3):201-11. Review. PubMed PMID: 11302287.